FOXO Technologies licenses epigenetics platform to LongevityFP in exclusive partnership

FOXO Technologies Inc. Class A Common Stock

FOXO Technologies Inc. Class A Common Stock

FOXO

0.00
  • FOXO Technologies entered an exclusive license partnership with LongevityFP Technologies to commercialize its epigenetics underwriting technology.
  • LongevityFP will pay a 3% royalty on net revenue, capped at USD 1.3 million.
  • Deal grants LongevityFP a 10-year option to acquire majority ownership of FOXO Labs, which holds the epigenetics IP.
  • If exercised, FOXO would retain a 40% equity interest in the resulting epigenetics enterprise.
  • Agreement reunites the platform with inventor Jon R. Sabes, former FOXO CEO, while FOXO shifts focus to healthcare services operations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FOXO Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605280833PRIMZONEFULLFEED9727990) on May 28, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.